RBC raises target for Illumina stock to USD 310
Published on 10/06/2026 at 10:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Illumina Inc. (ISIN US4523271090) was trading at EUR 263.63 at Lang & Schwarz on October 6, 2026 at 10:14 a.m. CEST, plus 0.74 percent versus the prior close of EUR 261.70. According to Markets Insider on October 5, 2026, RBC Capital analyst Dan Leonard raised the price target from USD 230.00 to USD 310.00 and kept an Outperform rating.
RBC sees clinical sales inflection
Markets Insider reported that RBC Capital linked the higher target to a multiple re-rating for Illumina's ecosystem, a clinical sales inflection and the possibility that tools companies gain from an artificial intelligence investment theme. The note also pointed to clinical sequencing as a central growth area.
The new USD 310.00 target is USD 80.00 above RBC Capital's previous USD 230.00 target. That 34.78 percent increase is a sharper change than the company's same-day euro price move, which was plus 0.74 percent against the Lang & Schwarz prior close.
Second-quarter revenue rose 9.50 percent
In its fiscal second-quarter 2026 results dated July 30, 2026, Illumina reported revenue of USD 1.16 billion, up 9.50 percent from USD 1.06 billion in fiscal second-quarter 2025. GAAP operating margin improved to 21.10 percent from 20.20 percent, while GAAP diluted earnings per share declined to USD 1.35 from USD 1.49.
The operating picture was mixed rather than uniformly stronger. Operating profit increased to USD 245.00 million from USD 214.00 million in the year-earlier quarter, but operating cash flow fell to USD 201.00 million from USD 234.00 million.
Fiscal 2026 outlook sets the next test
Illumina raised its fiscal 2026 revenue outlook to USD 4.60 billion to USD 4.64 billion from USD 4.52 billion to USD 4.62 billion. The company also lifted its non-GAAP diluted earnings-per-share outlook to USD 5.30 to USD 5.40 from USD 5.15 to USD 5.30, while maintaining its non-GAAP operating-margin outlook at 23.40 percent to 23.60 percent.
For investors, the key tension is visible in the contrast between the higher company outlook and the lower GAAP diluted earnings per share in the latest quarter. RBC Capital's valuation case therefore depends on clinical sequencing growth translating into sustained demand rather than on the quarterly revenue increase alone.
Illumina stock stays near its yearly high
Illumina's primary listing is on Nasdaq under ticker ILMN. The stock had a USD 44.4 billion market capitalization and a USD 73.86 to USD 296.25 52-week range as of October 5, 2026, leaving the primary-market quote near its yearly high while the Lang & Schwarz euro quote remained intraday.
The further course of trading is shown by the continuously updated real-time quote of Illumina stock.
Illumina stock facts
- Company: Illumina, Inc.
- ISIN: US4523271090
- Ticker: ILMN
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 6, 2026, 10:14 a.m. CEST: EUR 263.63
- Change versus prior close: plus 0.74 percent
- Prior close Lang & Schwarz (October 5, 2026): EUR 261.70
- Market capitalization: USD 44.4 billion (as of October 5, 2026)
- 52-week range: USD 73.86-296.25 (as of October 5, 2026)
- Sector / Industry: Healthcare / Medical Diagnostics and Research
- Index membership: S&P 500
